

URGENT: DRUG RECALL
INTERNAL RECALL #: 458

April 14, 2025

51991-00458-01214888
INDEPENDENT PHARM
1107 W MARKET CENTER DRIVE DIST-1107 MARKET
HIGH POINT, NC 27260

To Whom It May Concern:

Please be advised that **Breckenridge Pharmaceutical, Inc.** (Breckenridge) is voluntarily performing a Retail Level Recall of **Duloxetine Delayed-Release Capsules, USP, 30mg and 60mg**, manufactured by Towa Pharmaceutical Europe, S.L. Refer to accompanying image of the capsules. This Retail Level Recall affects the lots in the table below.

Only the lots listed in the table below are being recalled due to presence of Nitrosamine Drug Substance Related Impurity (NDSRI), N-nitroso-duloxetine, above the proposed interim limit.

Product	Size	NDC Number	Affected Lot #	Exp Date
Duloxetine Delayed-Release Capsules USP, 60 mg	1000-count	51991-748-10	240987C	04/2027
Duloxetine Delayed-Release Capsules USP, 60 mg	1000-count	51991-748-10	241014C	04/2027
Duloxetine Delayed-Release Capsules USP, 30 mg	90-count	51991-747-90	230201C	01/2026
Duloxetine Delayed-Release Capsules USP, 30 mg	90-count	51991-747-90	230471C	01/2026
Duloxetine Delayed-Release Capsules USP, 30 mg	1000-count	51991-747-10	230288C	01/2026

These impurities may increase the risk of cancer if people are exposed to them above acceptable levels over long periods of time. To date, Breckenridge is not aware of reports of adverse events that have been assessed to be related to this recall.

This recall is being initiated with the knowledge of the Food and Drug Administration and should be carried out to the **Retail Level.**

Please examine your stock, determine if you have any of the affected product lot numbers on hand and place affected product into quarantine. If you have any of the affected lots, please complete the "Business Recall Response Form" and return to Breckenridge's designated recall service provider – Qualanex LLC. Once Qualanex receives your completed response form, they will send you a Return Authorization which should be included with your recall return. Even if you do not have any of the affected lots, please complete the "Business Recall Response Form" with that information. You will also receive a Return Label (if you have not already received one) which you can use to return your recalled product.


Return Authorization requests can be made by email at recall@qualanex.com, via telephone at 1-800-505-9291, or by Fax at 1-847-737-3719.

Please take the following actions:

- 1) Check your inventory to see if you have any of the recalled product in stock, from the lot listed in the table above. If so, place the product under quarantine, and do not distribute.
- 2) Complete the enclosed "Business Recall Response Form" and return via facsimile to Qualanex, LLC at 1-847-737-3719 or via email at recall@qualanex.com.
- 3) If the product was further distributed, please notify sub-accounts to the retail level.

Please contact Qualanex at 1-800-505-9291, Monday – Friday from 9AM – 5PM (EST), should you have any questions or concerns regarding this recall.


Sincerely,


Jacquie Hibbert
Vice President, Quality Assurance

Breckenridge Pharmaceutical, Inc. | A Towa Company
Looking TOWArD the Future

URGENT: DRUG RECALL
INTERNAL RECALL #: 458

Duloxetine Delayed-Release Capsules USP, 30 mg



Duloxetine Delayed-Release Capsules USP, 60 mg



BUSINESS RECALL RESPONSE FORM
URGENT: DRUG RECALL
Internal Recall # 458

Product Name	Pack Size	NDC Number	Lots involved
Duloxetine Delayed-Release Capsules USP, 60 mg	1000-count	51991-748-10	240987C
Duloxetine Delayed-Release Capsules USP, 60 mg	1000-count	51991-748-10	241014C
Duloxetine Delayed-Release Capsules USP, 30 mg	90-count	51991-747-90	230201C
Duloxetine Delayed-Release Capsules USP, 30 mg	90-count	51991-747-90	230471C
Duloxetine Delayed-Release Capsules USP, 30 mg	1000-count	51991-747-10	230288C

This recall is being carried out at retail level.

Please fill out this form completely. By doing so, this will acknowledge that you have read and understand the recall instructions and have taken the appropriate action.

Customer Facility Name	
Address	
City, State, Zip	
Contact name	
Contact, Phone, Fax, Email	
Wholesaler Name and Address	

☐ I have read and understand the recall instructions provided on the recall notification letter dated April 14, 2025

☐ I have checked my stock for the recalled lots listed in the above table:

☐ Do not have any stock of the recalled items.

OR

☐ I have quarantined and listed in the table below the quantity of recall units I will be returning to QUALANEX as soon as possible.

Upon receipt of this Response Form, QUALANEX will issue a Return Authorization to be included with the product.

BUSINESS RECALL RESPONSE FORM
URGENT: DRUG RECALL
Internal Recall # 458

NDC	Lot #	Qty. Sealed bottles	Qty. Partial bottles	Notes
51991-748-10	240987C			
51991-748-10	241014C			
51991-747-90	230201C			
51991-747-90	230471C			
51991-747-10	230288C			

Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA's MedWatch Adverse Event Reporting program either online by completing and submitting the form at <https://www.accessdata.fda.gov/scripts/medwatch/index.cfm>.

FOR WHOLESALERS ONLY:

of Retail Pharmacies to be notified: _____

Please ~~return a copy of this completed~~ response form via facsimile to Qualanex, LLC at 1-847-737-3719 or via email at recall@qualanex.com.

Completed by: _____ Date: _____